Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities

Documenti analoghi

• Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model
  di: Seongmee Jeong, et al.
  Pubblicazione: (2025)
• Enhancing peripheral nerve regeneration through NaOH ‐based decellularization of human nerve tissue
  di: Subin Kim, et al.
  Pubblicazione: (2025)
• Antibody responses as correlates of protection against SARS‐CoV‐2 in the Omicron era: A 5‐month prospective cohort study in Korean healthcare workers’
  di: So Yun Lim, et al.
  Pubblicazione: (2024)
• Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies
  di: Wenhui Zhang, et al.
  Pubblicazione: (2025)
• Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV ‐2 Variants
  di: Qianwen Wang, et al.
  Pubblicazione: (2025)